Map Home
Type / to search with text or keywords
/
keyboard shortcut: Type "/" on your keyboard for a quick search
Search button
Loading...
Loading...
Scroll left
Grants
Citations
H-Index
Patents
News
Books
Scroll right
Collapse sidebar
Data issues & feedback
Adjust height of sidebar
KMap
People
Adjust height of sidebar
KMap
Profile
Muhammad Husnain
Assistant Professor, Medicine - (Clinical Scholar Track)
Medicine
Overview
Research
More
Collaboration
(11)
Akshay Amaraneni
Mutual work: 2 Publications﹒2 Grants
Collaboration Details
Francois Chu
Mutual work: 3 Grants
Collaboration Details
Michele Chu-Pilli
Mutual work: 4 Grants
Collaboration Details
Emmanuel Katsanis
Mutual work: 1 Publication﹒1 Grant
Collaboration Details
Abhijeet Kumar
Mutual work: 6 Publications
Collaboration Details
Page 1 of 3
Previous page
Next page
Grants
(9)
A Phase 1b/2, Open Label Umbrella Study Of Elranatamab (PF- 06863135), A B-Cell Maturation Antigen (BCMA) CD3 Bispecific Antibody, In Combination With Other Anti-Cancer Treatments In Participants With
Active
·
2023
·
$0 / $1.2M
·
External
Co-Investigator (COI)
cancer immunotherapy,
bispecific antibodies,
clinical trials,
bcma targeted therapy,
combination therapy
A Phase 3 Randomized Study Comparing Talquetamab SC in Combination With Daratumumab SC and Pomalidomide (Tai-DP) or Talquetamab SC in Combination With Daratumumab SC (Tal-D) Versus Daratumumab SC, Pom
Active
·
2023
·
$546.3K
·
External
Principal Investigator (PI)
clinical trials,
immunotherapy,
multiple myeloma,
combination therapy,
drug development
A Phase 1, Multicenter, Open-Label Study of CB-010, a CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy in Patients with Relapsed/Refractory B Cell Non-Hodgkin Lymphoma (ANTLER)
Active
·
2023
·
$464.7K
·
External
Principal Investigator (PI)
cell therapy,
cancer treatment,
crispr,
lymphoma,
clinical trial
An Escalation/Expansion, Open Label, Multicenter Study of Iadademstat and Gilteritnib in Patients With Relapsed or Refractory Acute Myeloid Leukemia (R/r Amil) With FMS-like Tyrosine Mutation (FLT3 mu
Active
·
2023
·
$0 / $116.3K
·
External
Co-Investigator (COI)
acute myeloid leukemia,
mutation,
combination therapy,
treatment
A PHASE 3 RANDOMIZED, OPEN-LABEL TRIAL OF SELINEXOR, POMALIDOMIDE, AND DEXAMETHASONE (SPd) VERSUS ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EloPd) IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE M
Active
·
2023
·
$12.6K
·
External
Principal Investigator (PI)
clinical trials,
multiple myeloma,
drug combination,
treatment comparison,
cancer therapy
Page 1 of 2
Previous page
Next page
Publications
(9)
Recent
Comparable Efficacy of Oral Bendamustine versus Intravenous Administration in Treating Hematologic Malignancies
2023
drug administration,
hematologic malignancies,
efficacy,
treatment
Hypophosphatemia and pre-infusion thrombocytopenia as biomarkers for CRS and ICANS after CAR T therapy
2023
biomarkers,
car t therapy,
crs,
icans,
hypophosphatemia
Refractory Pure Red Blood Cell Aplasia Secondary to Major ABO-Incompatible Allogeneic Stem Cell Transplantation Successfully Treated With Daratumumab
2023
stem cell transplantation,
red blood cell aplasia,
daratumumab,
allogeneic transplantation,
refractory treatment
Incidence of second primary malignancies in patients with multiple myeloma receiving anti-CD38 monoclonal antibodies: A systematic review and meta-analysis
2023
Waldenström macroglobulinemia: a review of pathogenesis, current treatment, and future prospects
2023
Feasibility and Efficacy of Partially Replacing Post-Transplantation Cyclophosphamide with Bendamustine in Pediatric and Young Adult Patients Undergoing Haploidentical Bone Marrow Transplantation
2022
bone marrow transplantation,
pediatric patients,
efficacy,
cyclophosphamide,
bendamustine
Impact of autologous transplantation on survival in patients with newly diagnosed multiple myeloma who have high-risk cytogenetics: A meta-analysis of randomized controlled trials
2022
CD38-Directed Therapies for Management of Multiple Myeloma
2021
A Living, Interactive Systematic Review and Network Meta-analysis of First-line Treatment of Metastatic Renal Cell Carcinoma
2021